Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    17919105 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Terminated HIV Immune and Virological Responses Following the Administration of IL-2 Either Alone or Combined to ALVAC-HIV 1433 and HIV Lipopeptides in Patients Treated Early With HAART During Primary Infection
Condition: HIV Infection
Interventions: Drug: IL-2;   Biological: LIPO-6T;   Biological: ALVAC VIH 1433

Indicates status has not been verified in more than two years